French-American company that deals with food safety, quality and sustainability Merieux NutriSciences announced on Monday that it has completed the acquisition of France-based testing and inspection organisation Bureau Veritas' food testing activities in Japan, Morocco, Southeast Asia and South Africa.
Following the recent finalisation of the deal in Canada and the US, this latest wave of closings marks a significant milestone in the previously announced global transaction, strengthening Mérieux NutriSciences' global position in food testing, inspection and certification (TIC).
This phase of the acquisition allows Merieux NutriSciences to establish a strong presence in the Japanese, Moroccan and Southeast Asian markets. The transaction also improves its capabilities in South Africa, including the addition of pharmaceutical testing solutions.
With the transaction, Merieux NutriSciences has included over 500 employees and integrated eight laboratories into its global network. This transaction is part of a broader agreement with Bureau Veritas encompassing its worldwide food laboratory testing activities, which include microbiological and chemical analysis, as well as molecular testing. Additional announcements about the completion of acquisitions in other regions, including laboratories across Asia-Pacific and Latin America, will follow as those transactions are finalised.
ContextVision partners with University of Washington to advance liver disease diagnostics
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
hVIVO to conduct RSV human challenge trial for Inhalon Biopharma
Moberg Pharma and Allderma announce launch of Terclara in Norway
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Sanofi secures China approval for Sarclisa in newly diagnosed multiple myeloma
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
H. Lundbeck A/S reports positive results from open-label extension of Phase 1b/2a bexicaserin trial
Invenra and Orion partner to develop bispecific antibody cancer therapies
Novo Nordisk Foundation awards record DKK10.1bn for health and sustainability initiatives
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor